Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2024-11-08 Interim / Quarterly Rep…
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2024
2024-11-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 7, 2024, reporting the issuance of a press release announcing financial results for the three and nine months ended September 30, 2024. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for certain regulatory purposes. The document is short (3639 characters) and primarily serves as an announcement of the earnings release rather than containing the financial results itself. According to the "Menu vs Meal" rule, such a document is classified as an Earnings Release (ER) since it announces quarterly financial results, but given the short length and nature, it is best classified as an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR).
2024-11-07 English
SC 13G/A
Major Shareholding Notification
2024-11-01 English
PRIMARY DOCUMENT
Director's Dealing
2024-09-26 English
PRIMARY DOCUMENT
Director's Dealing
2024-09-25 English
PRIMARY DOCUMENT
Director's Dealing
2024-09-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.